SEC Tracker
Get the app

Keros Therapeutics KROS

Christopher Rovaldi (Affiliate) plans to sell 85,306 KROS shares, about $1.3M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Sep 12, 2025
  2. Broker: UBS Financial Services Inc.
  3. Shares acquired by: Exercise of Stock Options
  4. 10b5-1 plan adopted: Aug 12, 2024

All of Christopher Rovaldi's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. CytoDyn CYDY public float $418M, Nov 30, 2025
  2. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  3. Cryoport CYRX public float $400M, Jun 30, 2025
  4. Capricor Therapeutics CAPR public float $399M, Jun 30, 2025
  5. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025